Browse > Article
http://dx.doi.org/10.5487/TR.2011.27.2.111

Toxicity Study of Streptococcus pneumoniae Vaccine Administrated Subcutaneously in Rats  

Park, Sin-Jeong (Jeollanamdo Biopharmaceutical Research Center)
Seo, Kook-Heon (Jeollanamdo Biopharmaceutical Research Center)
Han, Sang-In (Jeollanamdo Biopharmaceutical Research Center)
Publication Information
Toxicological Research / v.27, no.2, 2011 , pp. 111-118 More about this Journal
Abstract
This study was performed to evaluate the toxicity of polysaccharide-based Streptococcus pneumoniae vaccine in Specific Pathogen Free (SPF), Sprague-Dawley (SD) rats. S. pneumoniae vaccine was administrated subcutaneously each dose level of high (560 ${\mu}g$/rat), medium (280 ${\mu}g$/rat) and low (140 ${\mu}g$/rat) on days 0, 14, 28. The rats were observed for 2 weeks or 4 weeks after the final injection. During this test, there were no significant dose-dependent changes in body weight, water and food consumption. In urinalysis and serum chemistry, dose-related changes were not detected. In hematology, the percent of neutrophils and lymphocytes in white blood cells were changed significantly. According to the measurement of organ weight, only spleen weight was significantly increased in all groups of administration compared to the control group. In the histopathological examination, an antigen-deposit, vacuolated macrophages, infiltrated inflammatory cells and a formation of granulation tissue were observed at the site of an administration. These results are considered as an outcome by immune responses through a vaccination. Consequently, the results of this study demonstrated that S. pneumoniae vaccine has no toxicity when it was administrated subcutaneously three times in 2-week interval at a high dose of 560 ${\mu}g$/rat.
Keywords
Streptococcus pneumoniae; Polysaccharide; Vaccine;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Korea Food & Drug administration (2008): Guideline on Nonclinical Evaluation of Biopharmaceuticals, 11-147000 0-001713-14.
2 Korea Food & Drug administration (2008). Food & Drug statistical yearbook, 11-1470000-000023-10.
3 Meng, C., Lin, H., Huang, J., Wang, H., Cai, Q., Fang, L. and Guo, Y. (2009). Development of 5-valent conjugate pneumococcal protein A-capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease. Microb. Pathog., 47, 151-156.   DOI   ScienceOn
4 Pletz, M.W., Maus, U., Krug, N., Welte, T. and Lode, H. (2008). Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int. J. Antimicrob. Agents., 32, 199-206.   DOI   ScienceOn
5 Rao, M. and Alving, C.R. (2000). Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. mangala.rao@na.amedd.army.mil. Adv. Drug. Deliy. Rev., 41, 171-188.   DOI   ScienceOn
6 Richard, A.G., Thomas, J.K., Barbara, A.O. and Janis, K. (2003). Immunology (5th edition), W.H.Freeman, NewYork, pp. 335-336.
7 Ring, A., Weiser, J.N. and Tuomanen, E.I. (1998). Pneumococcal Trafficking across the Blood-Brain Barrier. Molecular Analysis of a Novel Bidirectional Pathway. J. Clin. Invest., 102, 347-360.   DOI   ScienceOn
8 Black, S., Shinefield, H., Fireman, B., Lewis, E., Ray, P., Hansen, J.R., Elvin, L., Ensor, K.M., Hackell, J., Siber, G., Malinoski, F., Madore, D., Chang, I., Kohberger, R., Watson, W., Austrian, R. and Edwards, K. (2000). Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J., 19, 187-195.   DOI   ScienceOn
9 Charles, A.J., Paul, T., Mark, W. and Mark, S. (2005). ImmunoBiology-the immune system in health and disease (6th edition), Garland Science, NewYork, pp. 12-23.
10 Daoust, V., Carlo, D.J., Zelther, J.Y. and Perry, M.B. (1981). Specific Capsular polysaccharide of Type 45 Streptococcus pneumonia (American Type 72). Infect. Immun., 32, 1028-1033.
11 Henriksen-Lacey, M., Bramwell, V.W., Christensen, D., Agger, E.M., Andersen, P. and Perrie, Y. (2010). Liposome based on dimethyldioctadecylammonium promote a depot effect and enhance immungenicity of soluble antigen. J. Control. Release., 142, 180-186.   DOI   ScienceOn
12 Fenske, D.B., Chonn, A. and Cullis, P.R. (2008). Liposomal Nanomedicines: An Emerging Field. Toxicol. Pathol., 36, 21-29.   DOI   ScienceOn
13 Hausdorff, W.P., Feikin, D.R. and Klugman, K.P. (2005). Epidemiological differences among pneumococcal serotypes. Lancet. Infect. Dis., 5, 83-93.   DOI   ScienceOn